Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
Author of the article:Published Jul 09, 2024 • 4 minute readSPRING, Texas, July 09, 2024 (GLOBE NEWSWIRE) — Io Therapeutics, ...
Read more